- Home
- >
- Bioscience
Researcher
Dr. Charles Sande
Principal Investigator
KEMRI | Wellcome Trust
Publications (15)
A complete list of publications by Dr. Charles Sande. Use the filters to refine by year, journal or keyword.
No publications match those filters.
-
2026
Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): Clinical Features and Wave Patterns
Lambisia, A. W. Nyiro, J. Githinji, G. Katama, et al.
Open Forum Infect Dis. 2026; 13:ofag084
-
2025
Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay
Waweru, G. Nyakundi, R. Kutima, B. Owuor, et al.
Viruses. 2025; 17
-
2025
Emergence and transmission dynamics of the FY.4 Omicron variant in Kenya
Musundi, S. Mwanga, M. Lambisia, A. Morobe, et al.
Virus Evol. 2025; 11:veaf035
-
2025
Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave
Lambisia, A. W. Katama, E. N. Moraa, E. Mwita, et al.
BMC Glob Public Health. 2025; 3:80
-
2025
Retaining African networks is urgent for global health
Bhiman, J. N. Serwanga, J. Ugwu, C. A. Vigan-Womas, et al.
Trends Microbiol. 2025; 33:1150-1154
-
2024
Inno4Vac Workshop Report Part 2: RSV-Controlled Human Infection Model (CHIM) Strain Selection and Immune Assays for RSV CHIM Studies, November 2021, MHRA, UK
Waldock, J. Cox, R. J. Engelhardt, O. G. Ascough, et al.
Influenza Other Respir Viruses. 2024; 18:e70013
-
2024
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
Terstappen, J. Hak, S. F. Bhan, A. Bogaert, et al.
Lancet Infect Dis. 2024; 24:e747-e761
-
2024
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
Lugano, D. Kutima, B. Kimani, M. Sigilai, et al.
BMC Infect Dis. 2024; 24:1474
-
2023
New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March-May 2023
Mwanga, M. J. Lambisia, A. W. Morobe, J. M. Murunga, et al.
Emerg Infect Dis. 2023; 29:2376-2379
-
2023
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Mazur, N. I. Terstappen, J. Baral, R. Bardaji, et al.
Lancet Infect Dis. 2023; 23:e2-e21
-
2022
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries
Carbonell-Estrany, X. Simoes, E. A. F. Bont, L. J. Gentile, et al.
Front Pediatr. 2022; 10:1033125
-
2021
Respiratory syncytial virus in young children: community cohort study integrating serological surveys, questionnaire and electronic health records, Born in Bradford cohort, England, 2008 to 2013
Zylbersztejn, A. Pembrey, L. Goldstein, H. Berbers, et al.
Euro Surveill. 2021; 26
-
2015
Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya
Nyiro, J. U. Sande, C. Mutunga, M. Kiyuka, et al.
Vaccine. 2015; 33:1797-801
-
2008
Identifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples
Okiro, E. A. Sande, C. Mutunga, M. Medley, et al.
J Clin Microbiol. 2008; 46:1659-62
-
2007
Comparison of strain-specific antibody responses during primary and secondary infections with respiratory syncytial virus
Scott, P. D. Ochola, R. Sande, C. Ngama, et al.
J Med Virol. 2007; 79:1943-50